Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

ConclusionsBintrafusp alfa showed signs of clinical efficacy with a manageable safety profile in patients with heavily pretreated, advanced esophageal adenocarcinoma.Clinical Trials RegistrationNCT02517398.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research